›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:Oncomine Precision Assay
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Thermo Fisher ScientificType:
Laboratory Developed Test
Related tests:
The Oncomine Precision Assay on the Ion Torrent Genexus System is a next-generation solution for genomic profiling to detect key biomarkers such as EGFR, ALK, BRAF, ROS1, NTRK, RET, or ERBB2 from formalin-fixed paraffin-embedded (FFPE) tissue or liquid biopsy specimens in one day. This assay is ideal for fast genomic profiling in clinical cancer research. It features carefully curated biomarker content spanning 50 genes based on the latest therapy developments, medical guidelines, and clinical trials.
Cancer:
Breast Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Glioma, Head and Neck Cancer, Melanoma, Non Small Cell Lung Cancer, Solid Tumor
Gene:
AKT1 (V-akt murine thymoma viral oncogene homolog 1), AKT2 (V-akt murine thymoma viral oncogene homolog 2), AKT3 (V-akt murine thymoma viral oncogene homolog 3), ALK (Anaplastic lymphoma kinase), AR (Androgen receptor), ARAF (A-Raf Proto-Oncogene)
See More ...
AKT1 (V-akt murine thymoma viral oncogene homolog 1), AKT2 (V-akt murine thymoma viral oncogene homolog 2), AKT3 (V-akt murine thymoma viral oncogene homolog 3), ALK (Anaplastic lymphoma kinase), AR (Androgen receptor), ARAF (A-Raf Proto-Oncogene), BRAF (B-raf proto-oncogene), CDK4 (Cyclin-dependent kinase 4), CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), CHEK2 (Checkpoint kinase 2), CTNNB1 (Catenin (cadherin-associated protein), beta 1), EGFR (Epidermal growth factor receptor), ER (Estrogen receptor), ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3), ERBB4 (erb-b2 receptor tyrosine kinase 4), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), FGFR4 (Fibroblast growth factor receptor 4), FLT3 (Fms-related tyrosine kinase 3), GNA11 (G Protein Subunit Alpha 11), GNAQ (G Protein Subunit Alpha Q), GNAS (GNAS Complex Locus), HER-2 (Human epidermal growth factor receptor 2), HRAS (Harvey rat sarcoma viral oncogene homolog), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), KIT (KIT proto-oncogene, receptor tyrosine kinase), KRAS (KRAS proto-oncogene GTPase), MAP2K1 (Mitogen-activated protein kinase kinase 1), MAP2K2 (Mitogen-activated protein kinase kinase 2), MET (MET proto-oncogene, receptor tyrosine kinase), NRAS (Neuroblastoma RAS viral oncogene homolog), NRG1 (Neuregulin 1), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2), NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3), NUTM1 (NUT Midline Carcinoma Family Member 1), PD-L1 (Programmed death ligand 1), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), PTEN (Phosphatase and tensin homolog), RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), RSPO2 (R-Spondin 2), RSPO3 (R-Spondin 3), SMO (Smoothened Frizzled Class Receptor), TP53 (Tumor protein P53), mTOR (Mechanistic target of rapamycin kinase)
Drug:
vorasidenib (S95032)
Method:
Next-Generation Sequencing (NGS)
